Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

IMVT Immunovant, Inc.

Trading 08-14 11:25:09 EDT

41.10

-0.72

-1.72%

High42.16	Low40.82	Vol148.07K
Open42.16	D1 Closing41.82	Amplitude3.20%
Mkt Cap8.48B	Tradable Cap3.25B	Total Shares206.40M
T/O6.09M	T/O Rate0.19%	Tradable Shares79.19M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"IMVT","market":"US","secType":"STK","nameCN":"Immunovant, Inc.","latestPrice":41.1,"timestamp":1786721106479,"preClose":41.82,"halted":0,"volume":148074,"delay":0,"changeRate":-0.017216642754662812,"floatShares":79191900,"shares":206402338,"eps":-2.817767,"marketStatus":"Trading","change":-0.72,"latestTime":"08-14 11:25:09 EDT","open":42.16,"high":42.16,"low":40.82,"amount":6092984.48976,"amplitude":0.032042,"askPrice":41.13,"askSize":4,"bidPrice":41.07,"bidSize":2,"shortable":3,"etf":0,"ttmEps":-2.817767,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1786737600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":41.82,"preHourTrading":{"tag":"盘前","latestPrice":41.86,"preClose":41.82,"latestTime":"09:18 EDT","volume":1651,"amount":69441.911916,"timestamp":1786713506808,"change":0.04,"changeRate":0.000956,"amplitude":0.066954},"postHourTrading":{"tag":"盘后","latestPrice":41.7161,"preClose":41.82,"latestTime":"19:57 EDT","volume":8663,"amount":362211.6686,"timestamp":1786665436298,"change":-0.1039,"changeRate":-0.002484,"amplitude":0.010481},"volumeRatio":0.377016,"impliedVol":0.6176,"impliedVolPercentile":0.5139},"requestUrl":"/m/hq/s/IMVT/tweets","defaultTab":"tweets","newsList":[{"id":"2657632405","title":"Immunovant, Inc. Reports Results for the Quarter Ended June 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2657632405","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657632405?lang=en_us&edition=fundamental","pubTime":"2026-08-06 21:32","pubTimestamp":1786023121,"startTime":"0","endTime":"0","summary":"Immunovant, Inc. reports results for the quarter ended June 30 - Earnings SummaryImmunovant, Inc.IMVT.OQreported a quarterly adjusted loss of 75 cents per share for the quarter ended June 30, lower th","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nL8N4431VO:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["PTH","BK4585","BK4139","ROIV","BK4007","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657563963","title":"Immunovant Fiscal Q1 2027 Results: IMVT-1402 Spending Widens Net Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657563963","media":"TradingKey","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657563963?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:06","pubTimestamp":1786018009,"startTime":"0","endTime":"0","summary":"Immunovant’s fiscal Q1 2027 results showed a GAAP net loss of $153.2 million, compared with $120.6 million a year earlier, while loss per share widened to $0.75 from $0.71. R&D expense rose about 41% to $142.6 million as IMVT-1402 clinical trials and contract manufacturing expanded, partly offset by lower batoclimab spending and a 32% decline in G&A expense. The company ended June 2026 with $797.8 million in cash and said its runway extends to a potential IMVT-1402 launch in Graves’ disease under the current operating plan.","market":"fut","thumbnail":"https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg","type":0,"news_type":0,"thumbnails":["https://resource.tradingkey.com/cdn/images/article/news/stock3.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tradingkey.com/news/earnings/262083546-tradingkey","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IMVT","BK4585","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657169636","title":"Immunovant reports Q2 EPS (75c), consensus (61c)","url":"https://stock-news.laohu8.com/highlight/detail?id=2657169636","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657169636?lang=en_us&edition=fundamental","pubTime":"2026-08-06 20:01","pubTimestamp":1786017718,"startTime":"0","endTime":"0","summary":"The company said, “Immunovant’s (IMVT) development plans for IMVT-1402 remain on track across all six announced indications. The Company expects to...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-reports-q2-eps-75c-consensus-61c-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-reports-q2-eps-75c-consensus-61c-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657335626","title":"Immunovant FY27 Q1 Net Loss Widens 27% to $153.2 Million; R&D Expenses Rise 40.9% to $142.6 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657335626","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657335626?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:20","pubTimestamp":1786015233,"startTime":"0","endTime":"0","summary":"Immunovant FY27 Q1 net loss widens 27% to $153.2 million; R&D expenses rise 40.9% to $142.6 millionImmunovant posted a wider net loss of USD 153.2 million, or USD 0.75 a share, for the quarter ended J","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nNDLnH5Br:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IMVT","BK4588","PTH","ROIV","BK4585","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633815","title":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633815","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633815?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:17","pubTimestamp":1786015029,"startTime":"0","endTime":"0","summary":"Earnings Flash (IMVT) Immunovant Posts Fiscal Q1 Loss $0.75 a Share, vs. FactSet Est of $0.65 Loss","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657680710","title":"Immunovant Q1 EPS $(0.75) Misses $(0.61) Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2657680710","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657680710?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014087,"startTime":"0","endTime":"0","summary":"Immunovant (NASDAQ:IMVT) reported quarterly losses of $(0.75) per share which missed the analyst consensus estimate of $(0.61) by 22.95 percent. This is a 5.63 percent decrease over losses of $(0.71) per share from the","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/08/60986784/immunovant-q1-eps-0-75-misses-0-61-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4139","BK4585","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657981638","title":"Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2657981638","media":"Reuters","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657981638?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:01","pubTimestamp":1786014062,"startTime":"0","endTime":"0","summary":"BRIEF-Immunovant Q1 Net Income USD -153.224 Million Vs. IBES Estimate USD -130.2 MillionAug 06 (Reuters) - Immunovant Q1 operating expenses USD 160.323 million.Q1 basic EPS USD -0.75","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX535BZQ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4139","BK4588","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657633904","title":"Immunovant, - Cash and Cash Equivalents Total $797.80 Mln as of June 30, 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2657633904","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657633904?lang=en_us&edition=fundamental","pubTime":"2026-08-06 19:00","pubTimestamp":1786014002,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260806:nPLX535BZQ:4","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4585","IMVT","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656552336","title":"J.P. Morgan Sticks to Their Buy Rating for Immunovant (IMVT)","url":"https://stock-news.laohu8.com/highlight/detail?id=2656552336","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656552336?lang=en_us&edition=fundamental","pubTime":"2026-08-04 22:21","pubTimestamp":1785853299,"startTime":"0","endTime":"0","summary":"J.P. Morgan analyst Brian Cheng maintained a Buy rating on Immunovant today and set a price target of $50.00. Cheng covers the Healthcare sector, f...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/j-p-morgan-sticks-to-their-buy-rating-for-immunovant-imvt-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1168165416","title":"Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1168165416","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1168165416?lang=en_us&edition=fundamental","pubTime":"2026-07-31 09:15","pubTimestamp":1785460503,"startTime":"0","endTime":"0","summary":"Abstract Immunovant, Inc. will report quarterly results on August 06, 2026 Pre-Market; this preview summarizes expected revenue, profitability, EPS trajectory, and institutional sentiment for the...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Earning Preview: Immunovant, Inc. Q2 revenue is expected to be flat, and institutional views are predominantly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655845522","title":"Roivant President, Immunovant CEO Eric Venker Sells USD 6.99 Million in Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2655845522","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655845522?lang=en_us&edition=fundamental","pubTime":"2026-07-30 09:00","pubTimestamp":1785373245,"startTime":"0","endTime":"0","summary":"Roivant President, Immunovant CEO Eric Venker sells USD 6.99 million in common sharesRoivant Sciences President and Immunovant CEO Eric Venker sold 200,000 common shares on July 27 at a weighted avera","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260730:nNDL6q3Bq2:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4007","BK4139","BK4588","PTH","ROIV","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654619030","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $59,700","url":"https://stock-news.laohu8.com/highlight/detail?id=2654619030","media":"Reuters","labels":["insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654619030?lang=en_us&edition=fundamental","pubTime":"2026-07-25 05:59","pubTimestamp":1784930385,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $59,700Immunovant director Atul Pande sold 1,500 shares on July 24, 2026 at USD 39.8.The sale followed the exercise of stock options ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260724:nNDLbGPzpM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["ROIV","BK4588","PTH","BK4139","IMVT","BK4007","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653490775","title":"Immunovant Updates Financial Calendar with First-quarter Results Release and Business Update Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2653490775","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653490775?lang=en_us&edition=fundamental","pubTime":"2026-07-24 04:26","pubTimestamp":1784838369,"startTime":"0","endTime":"0","summary":"Immunovant updates financial calendar with first-quarter results release and business update callImmunovant to report fiscal Q1 results for the period ended June 30, 2026 on Aug. 6, 2026, before the m","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260723:nNDL78ZZLp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["NDAQ","BK4139","IE00BN0W2W23.USD","BK4007","IE00BN0W2V16.EUR","IE00BN0W2T93.GBP","ROIV","LU2210150020.SGD","IE00B64PRP62.GBP","SG9999014005.SGD","BCDF","LU2095319765.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","IMVT","SG9999014021.USD","SG9999014013.SGD","PTH","LU0314104364.USD","BK4112","BK4588","SG9999014039.USD","BK4585","LU2210149790.SGD","IE00BKPKM429.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653979877","title":"Immunovant Announces Annual Shareholder Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2653979877","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653979877?lang=en_us&edition=fundamental","pubTime":"2026-07-23 04:11","pubTimestamp":1784751092,"startTime":"0","endTime":"0","summary":"Immunovant announces annual shareholder meetingImmunovant will hold its annual stockholders meeting virtually on Sept. 2, 2026.Shareholders will vote on electing three directors: Jacob Bauer, Douglas ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260722:nNDL5k6tVV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4585","BK4588","PTH","BK4139","ROIV","BK4007"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867102","title":"Immunovant CEO Eric Venker Disposes of Common Shares Worth $3.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867102","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649867102?lang=en_us&edition=fundamental","pubTime":"2026-07-07 05:02","pubTimestamp":1783371732,"startTime":"0","endTime":"0","summary":"Immunovant CEO Eric Venker disposes of common shares worth $3.46 millionImmunovant CEO Eric Venker acquired 92,188 common shares on July 1, 2026 at $14.46 per share.He disposed of 86,629 shares on Jul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260706:nNDLj4h1s:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","PTH","ROIV","BK4007","BK4588","IMVT","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648681288","title":"Chief Technology Officer Of Immunovant Sold 53% Of Their Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2648681288","media":"Simply Wall St.","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648681288?lang=en_us&edition=fundamental","pubTime":"2026-07-02 23:48","pubTimestamp":1783007321,"startTime":"0","endTime":"0","summary":"Some Immunovant, Inc. ( NASDAQ:IMVT ) shareholders may be a little concerned to see that the Chief Technology Officer...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/chief-technology-officer-of-immunovant-sold-53-of-their-shar","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-imvt/immunovant/news/chief-technology-officer-of-immunovant-sold-53-of-their-shar","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IMVT","BK4139","BK4588","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648756602","title":"Immunovant is Maintained at Buy by Citigroup","url":"https://stock-news.laohu8.com/highlight/detail?id=2648756602","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2648756602?lang=en_us&edition=fundamental","pubTime":"2026-07-01 02:59","pubTimestamp":1782845940,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IMVT/analyst-ratings(END) Dow Jones NewswiresJune 30, 2026 14:59 ET","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","BK4139","BK4585","IMVT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647537434","title":"Immunovant price target raised to $61 from $57 at Citi","url":"https://stock-news.laohu8.com/highlight/detail?id=2647537434","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2647537434?lang=en_us&edition=fundamental","pubTime":"2026-06-30 18:40","pubTimestamp":1782816009,"startTime":"0","endTime":"0","summary":"Citi raised the firm’s price target on Immunovant (IMVT) to $61 from $57 and keeps a Buy rating on the shares. Published first on TheFly – the ulti...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-61-from-57-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/immunovant-price-target-raised-to-61-from-57-at-citi-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4588","BK4585","IMVT","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646974395","title":"Immunovant Director Atul Pande Disposes of 1,500 Common Shares for $57,015","url":"https://stock-news.laohu8.com/highlight/detail?id=2646974395","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646974395?lang=en_us&edition=fundamental","pubTime":"2026-06-27 07:43","pubTimestamp":1782517435,"startTime":"0","endTime":"0","summary":"Immunovant director Atul Pande disposes of 1,500 common shares for $57,015Immunovant director Atul Pande exercised stock options for 1,500 common shares at $8.43 on June 26, 2026.Pande sold 1,500 comm","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDLSyS6p:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IMVT","BK4585","BK4007","BK4139","BK4588","ROIV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646393286","title":"Roivant Sciences President and Immunovant CEO Eric Venker Disposes of Common Shares Worth $6.63 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2646393286","media":"Reuters","labels":["shareholding","insiderTrades"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646393286?lang=en_us&edition=fundamental","pubTime":"2026-06-27 06:14","pubTimestamp":1782512070,"startTime":"0","endTime":"0","summary":"Roivant Sciences President and Immunovant CEO Eric Venker disposes of common shares worth $6.63 millionRoivant Sciences President and Immunovant CEO Eric Venker exercised stock options for 200,000 com","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260626:nNDL3gJsLK:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding,insiderTrades","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4007","BK4588","BK4585","ROIV","BK4139","IMVT"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.immunovant.com","stockEarnings":[{"period":"1week","weight":0.0523},{"period":"1month","weight":0.0787},{"period":"3month","weight":0.5213},{"period":"6month","weight":0.6241},{"period":"1year","weight":1.6318},{"period":"ytd","weight":0.6452}],"compareEarnings":[{"period":"1week","weight":0.0121},{"period":"1month","weight":0.0346},{"period":"3month","weight":0.0524},{"period":"6month","weight":0.141},{"period":"1year","weight":0.2062},{"period":"ytd","weight":0.1407}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragment crystallizable receptor, which is in Phase IIa clinical trials for the treatment of myasthenia gravis and thyroid eye disease, as well as completed initiation of Phase II clinical trials for the treatment of warm autoimmune hemolytic anemia. The company was incorporated in 2018 is headquartered in New York, New York. Immunovant, Inc. is a subsidiary of Roivant Sciences Ltd.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.081969},{"month":2,"riseRate":0.142857,"avgChangeRate":-0.118937},{"month":3,"riseRate":0.142857,"avgChangeRate":-0.068553},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.009383},{"month":5,"riseRate":0.428571,"avgChangeRate":0.091771},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.03669},{"month":7,"riseRate":0.625,"avgChangeRate":0.035685},{"month":8,"riseRate":0.625,"avgChangeRate":0.080657},{"month":9,"riseRate":0.857143,"avgChangeRate":0.12082},{"month":10,"riseRate":0.714286,"avgChangeRate":0.22916},{"month":11,"riseRate":0.571429,"avgChangeRate":0.058678},{"month":12,"riseRate":0.714286,"avgChangeRate":0.132246}],"exchange":"NASDAQ","name":"Immunovant, Inc.","nameEN":"Immunovant, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.47.1","shortVersion":"4.47.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Immunovant, Inc.,IMVT,Immunovant, Inc.股票,Immunovant, Inc.股票老虎,Immunovant, Inc.股票老虎国际,Immunovant, Inc.行情,Immunovant, Inc.股票行情,Immunovant, Inc.股价,Immunovant, Inc.股市,Immunovant, Inc.股票价格,Immunovant, Inc.股票交易,Immunovant, Inc.股票购买,Immunovant, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Immunovant, Inc.(IMVT),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Immunovant, Inc.(IMVT) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction